# A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC

> **NCT03678649** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 180 (estimated)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03678649
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-10
- **Primary completion:** 2020-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2018-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03678649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03678649, "A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03678649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*